Tectonic Therapeutic director granted 10,200 options
Tectonic Therapeutic, Inc. director Phillip B. Donenberg reported a compensation-related equity award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Tectonic Therapeutic, Inc. director Phillip B. Donenberg reported a compensation-related equity award. He received a stock option to acquire 10,200 shares of common stock at an exercise price of $28.56 per share, giving him the right, but not the obligation, to buy company stock at that price.
The option vests in full on the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a qualifying change in control, as long as he continues serving the company through that date. Following this grant, he holds 10,200 stock options directly, with an expiration date in 2036.
Insider Trade Summary
Grant/Award: 10,200 shares
Grant/Award
1 txn
Insider
Donenberg Phillip B.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 10,200 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,200 contracts (Direct)
Footnotes (1)
- F1. The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.
Key Figures
Option grant size: 10,200 options
Exercise price: $28.56 per share
Underlying shares: 10,200 shares
+3 more
6 metrics
Option grant size
10,200 options
Stock Option (Right to Buy) granted to director
Exercise price
$28.56 per share
Stock option strike price
Underlying shares
10,200 shares
Common Stock underlying the option
Expiration date
June 8, 2036
Option term end date
Post-grant derivative holdings
10,200 options
Total options held after transaction
Vesting latest date
June 9, 2027
Latest scheduled vesting condition
Key Terms
Stock Option (Right to Buy), Common Stock, Equity Incentive Plan, Change in Control, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
Common Stock financial
"underlying_security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Equity Incentive Plan financial
"as defined in the Issuer's 2024 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Change in Control financial
"or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan)"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Annual Meeting of Stockholders financial
"the date of the Issuer's 2027 Annual Meeting of Stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did TECX director Phillip B. Donenberg report?
Phillip B. Donenberg reported receiving a stock option grant for 10,200 shares of Tectonic Therapeutic common stock. The option is a compensation award, not an open-market trade, and gives him the right to buy shares at a fixed exercise price of $28.56.
What are the key terms of Phillip Donenberg’s TECX stock option grant?
The grant covers 10,200 underlying common shares at a $28.56 exercise price and expires on June 8, 2036. It vests in full on the earliest of June 9, 2027, the 2027 annual meeting, or a qualifying change in control, subject to continued service.
Does the Form 4 for TECX show any stock being bought or sold?
The Form 4 shows no open-market buying or selling of Tectonic Therapeutic shares. It reports a single compensation-related stock option grant coded as an acquisition (A), with no corresponding sale or exercise transactions disclosed in this filing.
How many TECX derivative securities does Phillip Donenberg hold after this transaction?
After the reported transaction, Phillip Donenberg holds 10,200 stock options relating to Tectonic Therapeutic common stock. These options were granted at a $28.56 exercise price and represent his direct derivative position as reflected in this specific Form 4 filing.
When will Phillip Donenberg’s TECX option award vest?
The option will vest in full at the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a defined change in control. Vesting in each case depends on Donenberg continuing to provide service to Tectonic Therapeutic through the applicable date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates